Eli Lilly and Company , the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating ...
Objective To evaluate the association between use of newer glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide, tirzepatide) and alcohol-related hospitalisations among adults with ...
If a senior loses weight but also loses significant muscle mass, is the treatment really a success?” GLP-1s are meant for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results